What is Surrozen?
Surrozen operates at the forefront of biotechnology, specializing in the intricate Wnt signaling pathway. The company's core innovation lies in its development of tissue-specific antibodies, engineered to harness and enhance the body's natural regenerative capabilities. These therapeutic candidates hold potential applications across a broad spectrum of challenging disease areas, including inflammatory bowel disease, hepatitis, various eye and hearing disorders, lung and airway conditions, and certain neurological conditions. The strategic focus on Wnt pathway modulation positions Surrozen to address unmet medical needs through novel biological approaches.
How much funding has Surrozen raised?
Surrozen has raised a total of $308M across 4 funding rounds:
Series A
$33M
Series B
$50M
Series C
$50M
Share Placement
$175M
Series A (2017): $33M with participation from The Column Group
Series B (2019): $50M led by The Column Group
Series C (2020): $50M supported by Hartford Healthcare Trust, The Column Group, and Horizons Ventures
Share Placement (2025): $175M, investors not publicly disclosed
Key Investors in Surrozen
The Column Group
The Column Group (TCG) is a venture ecosystem focused on advancing scientific innovation in the life sciences sector. With a history of funding key advancements in biotechnology, TCG has supported the formation and growth of 55 companies, generating $4.0 billion in returns for its partners.
Horizons Ventures
The Horizon Ventures partners have been helping entrepreneurs turn startup ventures into successful companies for over 20 years. We have worked with entrepreneurs with a vision that is both compelling and pragmatic and who appreciate our active involvement as much as equity financing.
Hartford Healthcare Trust
Undisclosed investor participating in the funding round.
What's next for Surrozen?
With the recent infusion of major strategic investment, Surrozen is poised for accelerated growth and the advancement of its promising drug candidates. The company's trajectory, marked by consistent capital raises including Series A, B, and C rounds, indicates a strong investor confidence in its scientific approach and therapeutic potential. This latest financing is anticipated to fuel further research and development, clinical trial progression, and potential expansion into new therapeutic indications. Surrozen's commitment to leveraging the Wnt pathway for tissue repair suggests a future focused on bringing innovative treatments to patients suffering from a range of debilitating diseases.
See full Surrozen company page
